TY - CHAP
T1 - Good laboratory and experimental practices for microRNA analysis in cardiovascular research
AU - Papaneophytou, Christos
AU - Galatou, Eleftheria
AU - Felekkis, Kyriacos
N1 - Publisher Copyright:
© 2021 Elsevier Inc. All rights reserved.
PY - 2021/1/1
Y1 - 2021/1/1
N2 - Cardiovascular diseases (CVDs) are a major cause of death worldwide, especially in developed countries. Noncoding RNA molecules and particularly circulating microRNAs (miRNAs) have become potential diagnostic, prognostic, and therapeutic biomarkers for CVDs. In the cardiovascular system, miRNAs regulate numerous biological functions while they have been implicated in the pathogenesis of several CVDs. miRNAs exhibit several advantages over other biological molecules (proteins, cytokines, and peptides), especially due to their high stability in circulation and under extreme pH and temperature conditions. However, it is still challenging to accurately determine miRNA levels and several preanalytical and analytical issues need to be addressed. Methodological heterogeneity in sample storage and handling, extraction and quantification of miRNAs, and data normalization resulted in inconsistency among different studies. In this chapter, we highlight the factors that must be taken into account when studying circulating miRNAs and we propose laboratory and experimental practices to ensure valid scientific inference.
AB - Cardiovascular diseases (CVDs) are a major cause of death worldwide, especially in developed countries. Noncoding RNA molecules and particularly circulating microRNAs (miRNAs) have become potential diagnostic, prognostic, and therapeutic biomarkers for CVDs. In the cardiovascular system, miRNAs regulate numerous biological functions while they have been implicated in the pathogenesis of several CVDs. miRNAs exhibit several advantages over other biological molecules (proteins, cytokines, and peptides), especially due to their high stability in circulation and under extreme pH and temperature conditions. However, it is still challenging to accurately determine miRNA levels and several preanalytical and analytical issues need to be addressed. Methodological heterogeneity in sample storage and handling, extraction and quantification of miRNAs, and data normalization resulted in inconsistency among different studies. In this chapter, we highlight the factors that must be taken into account when studying circulating miRNAs and we propose laboratory and experimental practices to ensure valid scientific inference.
KW - Biomarkers
KW - Cardiovascular diseases
KW - Diagnosis
KW - MicroRNAs
KW - Noncoding RNAs
KW - Plasma
KW - Serum
UR - http://www.scopus.com/inward/record.url?scp=85127185636&partnerID=8YFLogxK
U2 - 10.1016/B978-0-12-822258-4.00002-X
DO - 10.1016/B978-0-12-822258-4.00002-X
M3 - Chapter
AN - SCOPUS:85127185636
SP - 395
EP - 414
BT - Epigenetics in Cardiovascular Disease
PB - Elsevier
ER -